Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-03-01
2011-03-01
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S235100, C424S234100, C424S167100, C424S184100, C424S239100, C424S164100, C530S300000, C530S350000, C530S825000
Reexamination Certificate
active
07897158
ABSTRACT:
A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
REFERENCES:
patent: 4594336 (1986-06-01), Bizzini
patent: 5668255 (1997-09-01), Murphy
patent: 5919665 (1999-07-01), Williams
patent: 5989545 (1999-11-01), Foster et al.
patent: 6043042 (2000-03-01), Shone et al.
patent: 6372225 (2002-04-01), Matsuda
patent: 6395513 (2002-05-01), Foster et al.
patent: 6444209 (2002-09-01), Johnson et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6776990 (2004-08-01), Sachs et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 6822076 (2004-11-01), Bigalke et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7081529 (2006-07-01), Smith et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7193066 (2007-03-01), Chaddock et al.
patent: 7368532 (2008-05-01), Shone et al.
patent: 7419676 (2008-09-01), Dolly et al.
patent: 7422877 (2008-09-01), Dolly et al.
patent: 7452543 (2008-11-01), Chaddock et al.
patent: 7470661 (2008-12-01), Shone et al.
patent: 7674470 (2010-03-01), Shone et al.
patent: 2002/0044950 (2002-04-01), Shone et al.
patent: 2003/0049264 (2003-03-01), Foster et al.
patent: 2003/0147895 (2003-08-01), Shone et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 2004/0013687 (2004-01-01), Simpson et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2004/0208889 (2004-10-01), Sutton et al.
patent: 2004/0219637 (2004-11-01), Williams
patent: 2005/0244435 (2005-11-01), Shone et al.
patent: 2005/0255093 (2005-11-01), Shone et al.
patent: 2006/0051356 (2006-03-01), Foster et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2006/0110410 (2006-05-01), Shone et al.
patent: 2006/0204524 (2006-09-01), Ichtchenko et al.
patent: 2006/0216283 (2006-09-01), Foster et al.
patent: 2007/0184070 (2007-08-01), Shone et al.
patent: 2007/0259401 (2007-11-01), Dolly et al.
patent: 2009/0148888 (2009-06-01), Shone et al.
patent: 2009/0246827 (2009-10-01), Shone et al.
patent: 2010/0022751 (2010-01-01), Shone et al.
patent: 91/09871 (1991-07-01), None
patent: 92/15327 (1992-09-01), None
patent: 93/04191 (1993-03-01), None
patent: 93/15766 (1993-08-01), None
patent: 94/21300 (1994-09-01), None
patent: 94/21684 (1994-09-01), None
patent: 96/12802 (1996-05-01), None
patent: 96/33273 (1996-10-01), None
patent: 98/07864 (1998-02-01), None
patent: 98/08540 (1998-03-01), None
patent: 01/00839 (2001-01-01), None
patent: 01/08390 (2001-02-01), None
patent: 01/14570 (2001-03-01), None
patent: 02/44199 (2002-06-01), None
patent: 2004/024909 (2004-03-01), None
patent: WO 2006/059093 (2006-06-01), None
patent: WO 2007/138339 (2007-12-01), None
Foster et al, Toxicon, 2009, 54:587-592.
Foster et al, Botulinum Toxin, 2009, editor:Jankovic, pp. 349-359.
Shone et al, Infection and Immunity, Jul. 2009, 77/7:2795-2801.
Masuyer et al, BBRC, 2009, 381:50-53.
Sutton et al, Protein Expression and Purification, Mar. 2005, 40/1:31-41.
Nosoh, Y. et al, In:“Protein Stability and Stabilization through Protein Engineering, 1991”, chapter 7, p. 197.
Kumar et al, PNAS, 1991, 87:1337-1341.
Thomas E. Creighton, In: “Protein Structure: A Practical Approach”, 1989; pp. 184-186.
Thomas E. Creighton, In:“Proteins: Structures and Molecular Properties”, 1984, pp. 314-315.
Betley et al., BBRC, 1989, 162/3:1388-1395.
Binz et al., JBC, 1994, 269/3:1617-1620.
Binz, T. et al., “The Complete Sequence of Botulinum Neurotoxin type A and Comparison with Other Clostridial Neutoroxins,” J. Biol. Chem. 265:9153-9158, American Society for Biochemistry and Molecular Biology, Inc. (1990).
Bizzini, B., “Investigation of the Mode of Action of Tetanus Toxin with the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments,” in Bacterial Protein Toxins, Academic Press London, pp. 427-434 (1984).
Bowie et al., Science, 1990, 247:1306-1310.
Chaddock et al., Protein Expression and Purification, 2002, 25:219-228.
Application and Prosecution History for “Conjugates of Galatose-Binding Lectins and Clostridial Neurotoxins as Analgesics,” Duggan et al., U.S. Appl. No. 09/529,130, with a §371 date Jun. 22, 2000.
Application and Prosecution History for “Constructs for Delivery of Therapeutics Agents to Neuronal Cells,” Shone et al., U.S. Appl. No. 10/130,973, with a §371 date Jun. 25, 2002.
Application and Prosecution History for “Delivery of Superoxide Dismutase to Neuronal Cells,” Shone et al., U.S. Appl. No. 09/831,050, with a §371 date Aug. 20, 2001.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 09/763,669, with a §371 date May 29, 2001.
Application and Prosecution History for “Methods and Compounds for the Treatment of Mucus Hypersecretion,” Quinn et al., U.S. Appl. No. 10/633,698, filed Aug. 5, 2003.
Application and Prosecution History for “Recombinant Toxin Fragments,” Shone et al., U.S. Appl. No. 09/255,829, filed Feb. 23, 1999.
DasGupta et al., Biochemistry, 1987, 26:4162, Abstract #33 (Abstract Only).
DasGupta et al., Biochimie, 1990, 72:661-664.
East et al., International J. Systematic Bacteriology, 1996, 46/4:1105-1112.
Fujita et al., FEBS Letters, 1995, 376:41-44.
Gimenez et al., J. Protein Chemistry, 1993, 12/3:351-363.
Hausinger, A. et al., “Inhibition by Clostridial Neurotoxins of Calcium-Independent [3H]Noradrenaline Outflow from Freeze-Thawed Synaptosomes: Comparison with Synaptobrevin Hydrolysis,” Toxicon 33:1519-1530, Elsevier Science Ltd. (1995).
Hougten et al., Vaccine86, 1986, pp. 21-25, editors: Brown et al.
International Search Report for International Application No. PCT/GB97/02273, mailed Jan. 30, 1998.
Johnson et al., Toxicon, 2001, 39:1703-1722.
Kurazono, H. et al., “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A,” J. Biol. Chem. 267:14721-14729, American Society for Biochemistry and Molecular Biology, Inc. (1992).
Lacy et al., Nature, 1998, 5/10:898-902.
Lalli et al., TRENDS in Microbiology, Sep. 2003, 11/9:431-437.
Li, Y. et al., “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain,” Biochem. 33:7014-7020, American Chemical Society (1994).
Montecucco et al., Molecular Medicine Today, Oct. 1996, pp. 418-424.
Niemann, H., “Molecular Biology of Clostridial Neurotoxins,” In Sourcebook of Bacterial Protein Toxins, Ch. 15, Alouf, J.E. and J. H. Freer, eds., Academic Press Limited, London, pp. 303-348 (1991).
Poulain, B. et al., “Inhibition of Transmitter Release by Botulinum Neurotoxin A: Contribution of Various Fragments to the Intoxication Process,” Eur. J. Biochem. 185:197-203, Springer International (1989).
Rigoni et al., BBRC, 2001, 288:1231-1237.
Rosetto et al., Toxicon, 2001, 39:27-41.
Rudinger, J., “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” In Peptide Hormones, Parsons, J.A., ed., Univ
Chaddock John
Foster Keith Alan
Marks Philip
Quinn Conrad Padraig
Shone Clifford Charles
Minnifield N. M
Morris Manning & Martin LLP
Raimund Christopher W.
Syntaxin, Ltd
LandOfFree
Recombinant toxin fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant toxin fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant toxin fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663546